Xencor furnishes Phase 1 data, press release and slides (8-K)

Rhea-AI Filing Summary

Xencor, Inc. furnished an update under Regulation FD. The company held a conference call on October 24, 2025 to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3), early data from the ongoing Phase 1 dose-escalation study of XmAb541 (CLDN6 x CD3), and associated near-term clinical timelines.

Supporting materials were furnished, not filed, including a presentation (Exhibit 99.1) and a press release (Exhibit 99.2). The presentation is stated to be current as of April 29, 2025. The company noted that these materials are incorporated by reference as furnished under Item 7.01 and are not deemed filed for Section 18 purposes.

FALSE000132673200013267322025-10-242025-10-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________________________________________

FORM 8-K

___________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 24, 2025

___________________________________________________

XENCOR, INC.

(Exact name of registrant as specified in its charter)

___________________________________________________

Delaware			001-36182			20-1622502
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification Number)

465 North Halstead Street, Suite 200 Pasadena, California						91107
(Address of Principal Executive Offices)						(Zip Code)

(626) 305-5900

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

___________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol(s)			Name of Each Exchange on Which Registered
Common Stock, par value $0.01 per share			XNCR			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01. Regulation FD Disclosure.

Xencor, Inc. (the “Company”) held a conference call on October 24, 2025 to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3), early data from the ongoing Phase 1 dose-escalation study of XmAb541 (CLDN6 x CD3), and associated near-term clinical timelines. The Company has also made available on its website (www.xencor.com) presentation materials containing certain data from the ongoing clinical studies and certain forward-looking information.

The information contained in, or that can be accessed through, the Company’s website is not a part of this filing. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The presentation is current as of April 29, 2025 and the Company disclaims any obligation to update this material.

On October 24, 2025, the Company issued a press release announcing the initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3) and associated near-term clinical timelines. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.			Description
99.1			Presentation dated October 24, 2025.
99.2			Press release issued by Xencor, Inc. on October 24, 2025.
104			Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 24, 2025			XENCOR, INC.
			By:			/s/ Celia Eckert
						Celia Eckert
						General Counsel & Corporate Secretary

FAQ

What did XNCR announce in its 8-K?

Xencor furnished Reg FD materials summarizing initial Phase 1 results for XmAb819, early data for XmAb541, and near-term clinical timelines.

Which Xencor programs were discussed in the update?

The update covered XmAb819 (ENPP3 x CD3) and XmAb541 (CLDN6 x CD3), both in ongoing Phase 1 dose-escalation studies.

Are the materials considered filed or furnished?

They were furnished under Item 7.01 and are not deemed filed for Section 18 of the Exchange Act.

What exhibits were included with XNCR’s 8-K?

Exhibit 99.1 is a presentation dated October 24, 2025, and Exhibit 99.2 is a press release issued on October 24, 2025.

When were the conference call and press release issued?

Both occurred on October 24, 2025.

How current are the presentation materials?

The presentation is stated to be current as of April 29, 2025.